14 results
NOAC / DOAC Pharmacology and Prescribing Cheat Sheet
Novel (or Direct) Oral Anti-Coagulants
 • Rivaroxaban
 • Apixaban
NOAC / DOAC Pharmacology ... Novel (or Direct) Oral ... #Prescribing #hematology ... #management #Direct ... #Oral #AntiCoagulant
Oral anticoagulant dosing and bridging for VTE

- Dr. Joseph Shatzel @Clotmaster 

#VTE #DOAC #Bridging #Dosing #Oral
Oral anticoagulant ... Clotmaster #VTE #DOAC ... Bridging #Dosing #Oral ... Anticoagulant #Anticoagulation ... #Pharmacology #Hematology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
direct-acting oral ... anticoagulants (DOACs ... direct-acting oral ... Cancer #Algorithm #Anticoagulation ... #Management #Hematology
Anticoagulant Bridging

 • Switching from LMWH
 • Switching from UFH
 • Switching from DOAC to Warfarin
Switching from DOAC ... from Warfarin to DOAC ... Anticoagulant #Bridging #anticoagulation ... #pharmacology #management ... #hematology
DOAC Reversal
Emergency surgery or urgent procedure
Stop anticoagulant treatment; volume resuscitation and transfusion as needed
Antidotes:
 • Apixaban,
DOAC Reversal Emergency ... not available #DOAC ... #Reversal #NOAC ... #Oral #anticoagulant ... #hematology #management
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
DOAC, direct oral ... #DOAC #VTE #Malignancy ... Cancer #Algorithm #Anticoagulation ... #Management #Hematology
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
Myelodysplastic Syndrome ... Diagnosis and Management ... marrow) -dys- (abnormal ... Myelodysplastic #Syndrome ... #treatment #hematology
Effect of Direct Oral Anticoagulants on Hemostatic Tests
Horizontal bars correspond to the approximate range of detectability
Effect of Direct Oral ... thrombin time #doac ... #noac #anticoagulation ... #hematology #laboratory
Aplastic Anemia - Overview

Who?
• M = F
• 3 peaks:	1) Childhood	2) 15-25 years	3) >60 years

What?
• Aplastic anemia
Constitutional Syndromes ... (MDS) (normal or ... megakaryocytes and a normal ... Anemia #oncology #hematology ... #diagnosis #management
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Differentiation Syndrome ... 500 mg QD until normal ... Differentiation #Syndrome ... APML #diagnosis #management ... #hematology #oncology